Skip to content

Non-Hodgkin's Lymphoma

Font Size

Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Changes to This Summary (02 / 19 / 2013)


Revised text to state that with a median follow-up of 72 months, the event-free survival favored R-CHOP given every 2 weeks for six or eight cycles. Also revised statistics about OS favoring R-CHOP for only six cycles because of increased toxicity in the eight-cycle arm (cited Pfreundschuh et al. as reference 8).

Treatment for Aggressive, Noncontiguous Stage II/III/IV Adult NHL

Added text to state that a trial of 380 patients younger than 60 years with diffuse large B-cell lymphoma and an age-adjusted International Prognostic Index rating of 1 randomized treatment to ACVBP + rituximab versus CHOP + rituximab; with a median follow-up of 44 months, 3-year OS favored R-ACVBP (cited Récher et al. as reference 7 and level of evidence: 1iiA).

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.


WebMD Public Information from the National Cancer Institute

Last Updated: February 25, 2014
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
Next Article:

Today on WebMD

stem cells
What are they and why do we need them?
Lung cancer xray
See it in pictures, plus read the facts.
sauteed cherry tomatoes
Fight cancer one plate at a time.
Ovarian cancer illustration
Do you know the symptoms?
Vitamin D
New Treatments For Non-Hodgkins Lymphoma
Lifestyle Tips for Depression Slideshow
Pets Improve Your Health

WebMD Special Sections